These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 17240243)
1. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Wang JG; Nakhuda GS; Guarnaccia MM; Sauer MV; Lobo RA Am J Obstet Gynecol; 2007 Jan; 196(1):77.e1-5. PubMed ID: 17240243 [TBL] [Abstract][Full Text] [Related]
2. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325 [TBL] [Abstract][Full Text] [Related]
3. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Eldar-Geva T; Margalioth EJ; Gal M; Ben-Chetrit A; Algur N; Zylber-Haran E; Brooks B; Huerta M; Spitz IM Hum Reprod; 2005 Jul; 20(7):1814-9. PubMed ID: 15802320 [TBL] [Abstract][Full Text] [Related]
4. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354 [TBL] [Abstract][Full Text] [Related]
5. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Aleyasin A; Aghahoseini M; Mokhtar S; Fallahi P Acta Med Iran; 2011; 49(11):715-20. PubMed ID: 22131240 [TBL] [Abstract][Full Text] [Related]
6. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment. Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015 [TBL] [Abstract][Full Text] [Related]
7. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Das M; Gillott DJ; Saridogan E; Djahanbakhch O Hum Reprod; 2008 Sep; 23(9):2122-6. PubMed ID: 18550512 [TBL] [Abstract][Full Text] [Related]
8. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Siow Y; Kives S; Hertweck P; Perlman S; Fallat ME Fertil Steril; 2005 Oct; 84(4):938-44. PubMed ID: 16213847 [TBL] [Abstract][Full Text] [Related]
9. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152 [TBL] [Abstract][Full Text] [Related]
10. Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. Wachs DS; Coffler MS; Malcom PJ; Chang RJ J Clin Endocrinol Metab; 2007 May; 92(5):1871-4. PubMed ID: 17299061 [TBL] [Abstract][Full Text] [Related]
11. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fleming R; Harborne L; MacLaughlin DT; Ling D; Norman J; Sattar N; Seifer DB Fertil Steril; 2005 Jan; 83(1):130-6. PubMed ID: 15652898 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Nakhuda GS; Chu MC; Wang JG; Sauer MV; Lobo RA Fertil Steril; 2006 May; 85(5):1541-3. PubMed ID: 16566934 [TBL] [Abstract][Full Text] [Related]
13. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. Laven JS; Mulders AG; Visser JA; Themmen AP; De Jong FH; Fauser BC J Clin Endocrinol Metab; 2004 Jan; 89(1):318-23. PubMed ID: 14715867 [TBL] [Abstract][Full Text] [Related]
14. Serum anti-müllerian hormone levels in women with secondary amenorrhea. La Marca A; Pati M; Orvieto R; Stabile G; Carducci Artenisio A; Volpe A Fertil Steril; 2006 May; 85(5):1547-9. PubMed ID: 16616745 [TBL] [Abstract][Full Text] [Related]
15. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Mulders AG; Laven JS; Eijkemans MJ; de Jong FH; Themmen AP; Fauser BC Hum Reprod; 2004 Sep; 19(9):2036-42. PubMed ID: 15217995 [TBL] [Abstract][Full Text] [Related]
16. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785 [TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Carlsen SM; Vanky E; Fleming R Hum Reprod; 2009 Jul; 24(7):1732-8. PubMed ID: 19342396 [TBL] [Abstract][Full Text] [Related]
18. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. Pigny P; Merlen E; Robert Y; Cortet-Rudelli C; Decanter C; Jonard S; Dewailly D J Clin Endocrinol Metab; 2003 Dec; 88(12):5957-62. PubMed ID: 14671196 [TBL] [Abstract][Full Text] [Related]
19. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Chu MC; Carmina E; Wang J; Lobo RA Fertil Steril; 2005 Dec; 84(6):1685-8. PubMed ID: 16359965 [TBL] [Abstract][Full Text] [Related]
20. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders. Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]